Barclays’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33M | Sell |
180,000
-100
| -0.1% | -$18.4K | 0.01% | 885 |
|
|
2025
Q4 | $31.7M | Buy |
180,100
+180,000
| +180,000% | +$29.4M | 0.01% | 998 |
|
|
2025
Q3 | $14K | Buy |
+100
| New | +$13.5K | ﹤0.01% | 4990 |
|
|
2025
Q1 | – | Sell |
-8,200
| Closed | -$1.25M | – | 5272 |
|
|
2024
Q4 | $1.25M | Sell |
8,200
-22,600
| -73% | -$3.81M | ﹤0.01% | 3222 |
|
|
2024
Q3 | $5.97M | Buy |
+30,800
| New | +$6.44M | ﹤0.01% | 1936 |
|
|
2024
Q2 | – | Sell |
-40,800
| Closed | -$8.8M | – | 4887 |
|
|
2024
Q1 | $8.8M | Buy |
40,800
+15,000
| +58% | +$3.51M | ﹤0.01% | 1485 |
|
|
2023
Q4 | $6.68M | Buy |
25,800
+18,200
| +239% | +$4.47M | ﹤0.01% | 1855 |
|
|
2023
Q3 | $1.95M | Sell |
7,600
-50,200
| -87% | -$13.4M | ﹤0.01% | 1918 |
|
|
2023
Q2 | $16.5M | Buy |
57,800
+36,400
| +170% | +$10.8M | 0.01% | 794 |
|
|
2023
Q1 | $5.95M | Sell |
21,400
-99,100
| -82% | -$27.4M | ﹤0.01% | 1428 |
|
|
2022
Q4 | $33.4M | Buy |
+120,500
| New | +$34M | 0.01% | 660 |
|
|
2022
Q3 | – | Sell |
-142,500
| Closed | -$29.1M | – | 4794 |
|
|
2022
Q2 | $29.1M | Buy |
+142,500
| New | +$29.1M | 0.02% | 564 |
|
|
2022
Q1 | – | Sell |
-84,500
| Closed | -$20.3M | – | 4968 |
|
|
2021
Q4 | $20.3M | Buy |
+84,500
| New | +$21.7M | 0.01% | 939 |
|
|
2021
Q1 | – | Sell |
-88,100
| Closed | -$21.6M | – | 4701 |
|
|
2020
Q4 | $21.6M | Buy |
88,100
+26,300
| +43% | +$6.78M | 0.01% | 807 |
|
|
2020
Q3 | $17.5M | Sell |
61,800
-1,400
| -2% | -$390K | 0.01% | 798 |
|
|
2020
Q2 | $16.9M | Sell |
63,200
-58,500
| -48% | -$17.6M | 0.01% | 718 |
|
|
2020
Q1 | $38.5M | Sell |
121,700
-75,800
| -38% | -$23M | 0.03% | 390 |
|
|
2019
Q4 | $58.6M | Buy |
197,500
+10,400
| +6% | +$2.89M | 0.03% | 437 |
|
|
2019
Q3 | $43.6M | Buy |
187,100
+24,300
| +15% | +$5.66M | 0.03% | 515 |
|
|
2019
Q2 | $38.1M | Buy |
162,800
+63,000
| +63% | +$14.5M | 0.02% | 588 |
|
|
2019
Q1 | $23.6M | Sell |
99,800
-116,600
| -54% | -$36.7M | 0.02% | 755 |
|
|
2018
Q4 | $65.1M | Sell |
216,400
-44,600
| -17% | -$14.2M | 0.05% | 289 |
|
|
2018
Q3 | $92.2M | Buy |
261,000
+66,400
| +34% | +$22.9M | 0.06% | 225 |
|
|
2018
Q2 | $56.5M | Buy |
194,600
+14,000
| +8% | +$3.94M | 0.05% | 326 |
|
|
2018
Q1 | $49.5M | Sell |
180,600
-27,400
| -13% | -$8.51M | 0.04% | 427 |
|
|
2017
Q4 | $66.3M | Sell |
208,000
-33,100
| -14% | -$10.6M | 0.05% | 298 |
|
|
2017
Q3 | $75.5M | Buy |
241,100
+28,200
| +13% | +$8.35M | 0.08% | 205 |
|
|
2017
Q2 | $57.8M | Buy |
212,900
+112,300
| +112% | +$29.7M | 0.06% | 240 |
|
|
2017
Q1 | $27.5M | Buy |
100,600
+6,400
| +7% | +$1.81M | 0.03% | 434 |
|
|
2016
Q4 | $26.7M | Buy |
94,200
+11,300
| +14% | +$3.35M | 0.03% | 473 |
|
|
2016
Q3 | $25.9M | Sell |
82,900
-51,000
| -38% | -$15.1M | 0.03% | 439 |
|
|
2016
Q2 | $32.4M | Buy |
133,900
+17,800
| +15% | +$4.69M | 0.04% | 350 |
|
|
2016
Q1 | $30.2M | Sell |
116,100
-225,300
| -66% | -$59.5M | 0.05% | 352 |
|
|
2015
Q4 | $104M | Sell |
341,400
-268,200
| -44% | -$77.1M | 0.13% | 137 |
|
|
2015
Q3 | $177M | Buy |
609,600
+117,300
| +24% | +$38.7M | 0.21% | 71 |
|
|
2015
Q2 | $198M | Sell |
492,300
-80,400
| -14% | -$32.3M | 0.22% | 57 |
|
|
2015
Q1 | $242M | Buy |
572,700
+335,100
| +141% | +$132M | 0.28% | 48 |
|
|
2014
Q4 | $80.5M | Buy |
237,600
+74,900
| +46% | +$24.2M | 0.08% | 208 |
|
|
2014
Q3 | $53.7M | Sell |
162,700
-150,200
| -48% | -$49.5M | 0.05% | 302 |
|
|
2014
Q2 | $98.6M | Sell |
312,900
-132,800
| -30% | -$40M | 0.1% | 152 |
|
|
2014
Q1 | $136M | Buy |
445,700
+178,100
| +67% | +$56.5M | 0.15% | 105 |
|
|
2013
Q4 | $74.7M | Sell |
267,600
-79,700
| -23% | -$20.6M | 0.08% | 227 |
|
|
2013
Q3 | $83.4M | Buy |
347,300
+66,800
| +24% | +$15M | 0.1% | 165 |
|
|
2013
Q2 | $60.4M | Buy |
+280,500
| New | +$59.9M | 0.08% | 215 |
|
Other funds holding BIIB
VCM
VPM
Barclays's BIIB Position: Q1 2026 in Review
Barclays reduced its Biogen (BIIB) stake by 58% in Q1 2026, selling an estimated $139M and leaving 551,474 shares worth $101M. The position accounts for 0.02% of the portfolio, ranked #483.
Barclays first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $230M in Q4 2025. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Barclays held 551,474 shares of Biogen worth $101M as of Q1 2026.
- Barclays sold 753,533 Biogen shares in Q1 2026, an estimated $139M.
- Biogen made up 0.02% of Barclays's portfolio in Q1 2026, its #483 holding.
- Barclays first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Barclays's Biogen position peaked at $230M in Q4 2025.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.